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the Omni pump, which was a multi chamber pump capable of
running four medications at one time and had unique tubing.
The Omni was able to run syringe medications as well as
medications in bags. The implementation forced Nursing
Practice Council (NPC) to brainstorm a line and pump set-up
thatwould provide an equivalent process andworkﬂowas the
Omni. Unfortunately, the Sigma can only run one bag medi-
cation at a time and does not have the capability to run a
syringe medication. The new set-up would require four Sigma
pumps and two syringe pumps to replace the one Omni.
METHOD: Two months prior to implementation, NPC
created a poster displaying a line set-up that could accom-
modate the needs to administer multiple IV medications
simultaneously per patient into a double lumen Hickman. In
addition, NPC implemented a standardized pump set-up to
supplement the line set-up by creating an “BMT Amplatz
pole” order where every patient admitted receives the
pumps pre set-up from supply chain. Monthly audits were
done to check staff compliance and were reported in a
monthly unit newsletter. Yearly competencies are used to
evaluation assimilation of knowledge. A survey will be con-
ducted showing staff satisfaction.
RESULTS: Since implementation of the standard line and
pump set-up, our cyclosporine line contamination has been
zero, which is a decrease. Based on ICAREs, Our medication
errors related to infusion in the wrong lumen and in-
compatibilities with other medications has decreased from 12
in 2011, eight in 2012 and two in 2013 to date. We continue to
have low BSI rates that are below the nation average. From
informal verbal surveys, we have heard an increase in staff
satisfaction related to productivity and time management.
CONCLUSION: Based on the results, we know that the stan-
dardization has decreased medication errors and increased
staff satisfaction. We continue to evaluate the effectiveness
of the standardization set-up and continue to look for ways
to improve patient care and safety.
171
Variation in Inpatient Costs of Hematopoietic Cell
Transplantation Among Transplant Centers in the United
States
Viengneesee Thao 1, Ezra Golberstein 2, William Thomas 2,
Katy Backes Kozhimannil 2, Lih-Wen Mau3, Jaime M. Preussler 4,Figure 1. Adjusted mean costs of initial HCT hospitalizations in 2008-2010
Figure 1. Ranked hospital-mean autologous HCT costs (n ¼ 32) and allogeneic HCT
conﬁdence intervals, and the size of the plotting character is proportional to the hospi
indicated with squares.Ellen Denzen 5, Navneet S. Majhail 6. 1 Patient and Health
Professional Services, National Marrow Donor Program,
Minneapolis, MN; 2University of Minnesota, Minneapolis, MN;
3National Marrow Donor Program, Minneapolis, MN; 4 Patient
and Health Professional Services, National Marrow Donor
Program, Be The Match, Minneapolis, MN; 5 Patient and Health
Professional Services, The National Donor Marrow Program
(NMDP), Minneapolis, MN; 6 Blood and Marrow Transplant
Program, Cleveland Clinic Foundation, Cleveland, OH
Transplant centers vary in their practices for evaluation,
treatment, and follow-up for patients receiving hematopoi-
etic cell transplantation (HCT). This variation among centers
has the potential to cause variation in costs of HCT. To
characterize differences in costs of autologous (auto) and
allogeneic (allo) HCT by hospital, we conducted a retro-
spective cohort study using the Nationwide Inpatient Sample
(NIS). The NIS captures hospital utilization and costs, on a
stratiﬁed sample of US hospitals. ICD9 diagnosis and proce-
dure codes were used to identify hospitalizations for HCT
from 2008-2010. Costs were measured by applying a cost-to-
charge ratio, were discounted to 2008 dollars and log-
transformed due to high skewedness. Analyses were
restricted to hospitals that performed  30 HCT/year for
patients  18 years, and stratiﬁed by transplant type. Our
ﬁnal cohort included 32 hospitals that performed allo HCT
(1,932 patients) and 22 hospitals that performed auto HCT
(3,164 patients). Linear regression was performed to assess
associations between costs and characteristics of patients
(age, gender, race, payer type, diagnosis and Elixhauser co-
morbidity index) and hospitals (hospital volume, ownership,
and teaching status). Adjusting for these characteristics did
not change the rank ordering of hospitals, and differences in
cost remained signiﬁcant (p<0.001). Overall, adjusted mean
cost among hospitals performing auto HCT was $47,990 and
costs varied by a factor of three. Among hospitals performing
allo HCT, adjusted mean cost was $86,580 with costs that
varied by a factor of ﬁve (Figure 1). A limitation of the NIS is
that data only includes initial HCT hospitalizations; hence,
we could not account for costs associated with outpatient
care and subsequent hospitalizations. In conclusion, we
found signiﬁcant variation in costs of HCT independent of
patient demographics and case mix. Future research should
investigate factors that inﬂuence cost variation and whether
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